Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)

Acta Neuropathologica

Volumn 130, Issue 6, 2015, Pages 751-764

  Bauer, Jan ^a   Gold, Ralf ^b   Adams, Ortwin ^c   Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

^b ST JOSEF HOSPITAL   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Immune reconstitution inflammatory syndrome; JC virus; Neuropathology; Progressive multifocal leukoencephalopathy; T cell cytotoxicity

Indexed keywords

BONE MARROW CELL; CELL DESTRUCTION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE EXACERBATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATION; JC VIRUS; KIDNEY CELL; MORBIDITY; MORTALITY; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; OPPORTUNISTIC INFECTION; POLYOMAVIRUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIRUS CELL INTERACTION; VIRUS LATENCY; COMPLICATION; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PATHOLOGY; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; VIROLOGY;

HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; POLYOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 84947614974     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1471-7     Document Type: Review

References (113)

1. Aksamit AJ, Gendelman HE, Orenstein JM, Pezeshkpour GH (1990) AIDS-associated progressive multifocal leukoencephalopathy (PML): comparison to non-AIDS PML with in situ hybridization and immunohistochemistry. Neurology 40:1073–1078
2. Antoniol C, Stankoff B (2014) Immunological markers for PML prediction in MS patients treated with Natalizumab. Front Immunol 5:668
3. Aoki N, Mori M, Kato K, Sakamoto Y, Noda K, Tajima M, Shimada H (1996) Antibody against synthetic multiple antigen peptides (MAP) of JC virus capsid protein (VP1) without cross reaction to BK virus: a diagnostic tool for progressive multifocal leukoencephalopathy. Neurosci Lett 205:111–114
4. Assetta B, Maginnis MS, Gracia Ahufinger I, Haley SA, Gee GV, Nelson CDS, O’Hara BA, S-aA Allen Ramdial, Atwood WJ (2013) 5-HT2 receptors facilitate JC polyomavirus entry. J Virol 87:13490–13498
5. Astrom KE, Mancall EL, Richardson EP Jr (1958) Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 81:93–111
6. Barac-Latas V, Suchanek G, Breitschopf H, Stuehler A, Wege H, Lassmann H (1997) Patterns of oligodendrocyte pathology in coronavirus-induced subacute demyelinating encephalomyelitis in the Lewis rat. Glia 19:1–12
7. Barnett MH, Parratt JD, Cho ES, Prineas JW (2009) Immunoglobulins and complement in postmortem multiple sclerosis tissue. AnnNeurol 65:32–46
8. Bayliss J, Karasoulos T, McLean CA (2012) Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain. Brain pathology 22:329–336
9. Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Bonington A (2003) BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection 31:374–378
10. Bellizzi A, Anzivino E, Rodio DM, Palamara AT, Nencioni L, Pietropaolo V (2013) New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol 2013:839719
11. Bernal-Cano F, Joseph JT, Koralnik IJ (2007) Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 13:474–476
12. Bien CG, Bauer J, Deckwerth TL, Wiendl H, Deckert M, Wiestler OD, Schramm J, Elger CE, Lassmann H (2002) Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen’s encephalitis. Ann Neurol 51:311–318
13. Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, Sutton I, Lassmann H, Bauer J (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638
14. Boldorini R, Cristina S, Vago L, Tosoni A, Guzzetti S, Costanzi G (1993) Ultrastructural studies in the lytic phase of progressive multifocal leukoencephalopathy in AIDS patients. Ultrastruct Pathol 17:599–609
15. Bollag B, Hofstetter CA, Reviriego-Mendoza MM, Frisque RJ (2010) JC virus small T antigen binds phosphatase PP2A and Rb family proteins and is required for efficient viral DNA replication activity. PLoS One 5:e10606
16. Bollag B, Prins C, Snyder EL, Frisque RJ (2000) Purified JC virus T and T′ proteins differentially interact with the retinoblastoma family of tumor suppressor proteins. Virology 274:165–178
17. Booss J, Esiri MM (2003) Viral encephalitis in humans. ASM Press, Washington, D.C.
18. Budka H (1983) Immunohistological demonstration of serum proteins and structural and viral antigens in paraffin sections of nervous tissues. Ann N Y Acad Sci 420:176–184
19. Budka H, Shah KV (1983) Papovavirus antigens in paraffin sections of PML brains. Prog Clin Biol Res 105:299–309
20. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834–4840
21. Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, Zhao Z, Duda P (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 19:351–358
22. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52:623–625
23. Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84:1068–1074
24. Dang X, Vidal JE, Oliveira AC, Simpson DM, Morgello S, Hecht JH, Ngo LH, Koralnik IJ (2012) JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol 93:175–183
25. Dang X, Wuthrich C, Gordon J, Sawa H, Koralnik IJ (2012) JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One 7:e35793
26. De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, Monforte AD, Antinori A (2000) The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182:1077–1083
27. Di Pauli F, Berger T, Walder A, Maier H, Rhomberg P, Uprimny C, Steurer M, Stockhammer G (2014) Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature. J Clin Virol 60:424–427
28. Dorries K, Johnson RT, ter Meulen V (1979) Detection of polyoma virus DNA in PML-brain tissue by (in situ) hybridization. J Gen Virol 42:49–57
29. + individual. Neurology 61:775–782
30. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127:1970–1978
31. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380–1383
32. Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 33:579–589
33. Epperla N, Medina-Flores R, Mazza JJ, Yale SH (2014) Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy. WMJ 113:242–245
34. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471–506
35. Gasnault J, Kahraman M, de Herve MGDG, Durali D, Delfraissy JF, Taoufik Y (2003) Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. Aids 17:1443–1449
36. Gheuens S, Wuthrich C, Koralnik IJ (2013) Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 8:189–215
37. Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A (2014) Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 370:486–488
38. Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Luke W, Lazzarin A, Weber T, Cinque P (2000) Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30:95–99
39. Gordon J, Gallia GL, Del Valle L, Amini S, Khalili K (2000) Human polyomavirus JCV and expression of myelin genes. J Neurovirol 6(Suppl 2):S92–S97
40. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204:103–114
41. Guillaume B, Sindic CJ, Weber T (2000) Progressive multifocal leukoencephalopathy: simultaneous detection of JCV DNA and anti-JCV antibodies in the cerebrospinal fluid. Eur J Neurol 7:101–106
42. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yainnoutsos C, Major E, Millar L, Timpone J (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338:1345–1351
43. Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 85:1177–1178
44. Hoepner R, Dahlhaus S, Kollar S, Zurawski B, Chan A, Kleiter I, Gold R, Hellwig K (2014) Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy. Ther Adv Neurol Disord 7:3–6
45. Isidoro L, Pires P, Rito L, Cordeiro G (2014) Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep
46. Itoyama Y, Webster HD, Sternberger NH, Richardson EP Jr, Walker DL, Quarles RH, Padgett BL (1982) Distribution of papovavirus, myelin-associated glycoprotein, and myelin basic protein in progressive multifocal leukoencephalopathy lesions. Ann Neurol 11:396–407
47. Johnson EM, Wortman MJ, Dagdanova AV, Lundberg PS, Daniel DC (2013) Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol 2013:197807
48. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdova E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O’Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radu EW, Sorensen PS, King J (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745–758
49. Khalili K, White MK (2006) Human demyelinating disease and the polyomavirus JCV. Multiple sclerosis 12:133–142
50. Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA, Vernazza P, Bernasconi E, Viscidi R, Battegay M, Hirsch HH (2009) JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 83:4404–4411
51. Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijlens ML, Wattjes MP (2014) PML–IRIS during fingolimod diagnosed after Natalizumab discontinuation. Case Rep Neurol Med 2014:307872
52. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T (2012) Update on PML and PML–IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71:604–617
53. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DWG, Miller E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115–123
54. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, Lifton M, Letvin NL (2002) Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168:499–504
55. Koralnik IJ, Wuthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, Morgello S (2005) JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 57:576–580
56. Kuchelmeister K, Gullotta F, Bergmann M, Angeli G, Masini T (1993) Progressive multifocal leukoencephalopathy (PML) in the acquired immunodeficiency syndrome (AIDS). A neuropathological autopsy study of 21 cases. Pathol Res Pract 189:163–173
57. Kurmann R, Weisstanner C, Kardas P, Hirsch HH, Wiest R, Lammle B, Furrer H, Du Pasquier R, Bassetti CL, Sturzenegger M, Krestel H (2015) Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. J Neurovirol
58. Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57:141–146
59. + T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 81:3361–3368
60. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC (2003) Granzyme B: a natural born killer. Immunol Rev 193:31–38
61. Love S, Louis DN, Ellison DW (eds) (2008) Greenfield’s Neuropathology, 8th edn. Hodder Arnold, London
62. Lundstig A, Dillner J (2006) Serological diagnosis of human polyomavirus infection. Adv Exp Med Biol 577:96–101
63. Maginnis MS, Nelson CD, Atwood WJ (2014) JC polyomavirus attachment, entry, and trafficking: unlocking the keys to a fatal infection. J Neurovirol
64. + T cells in PML–IRIS during HIV infection. Neurology 81:964–970
65. (+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome. Acta Neuropathol 129:463–465
66. Metz I, Radue EW, Oterino A, Kumpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Hausler D, Bruck W (2012) Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 123:235–245
67. Moenster RP, Jett RA (2012) Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm 69:496–498
68. Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM (2008) Cortical demyelination in PML and MS: similarities and differences. Neurology 70:336–343
69. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO (1996) JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 70:7004–7012
70. Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CDS, Feizi T, Atwood WJ, Stehle T (2010) Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8:309–319
71. Okada Y, Sawa H, Endo S, Orba Y, Umemura T, Nishihara H, Stan AC, Tanaka S, Takahashi H, Nagashima K (2002) Expression of JC virus agnoprotein in progressive multifocal leukoencephalopathy brain. Acta Neuropathol 104:130–136
72. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1:1257–1260
73. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K (2008) Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 64:379–387
74. Pietropaolo V, Fioriti D, Simeone P, Videtta M, Di Taranto C, Arancio A, Orsi N, Degener AM (2003) Detection and sequence analysis of human polyomaviruses DNA from autoptic samples of HIV-1 positive and negative subjects. Int J Immunopathol Pharmacol 16:269–276
75. Pina-Oviedo S, Urbanska K, Radhakrishnan S, Sweet T, Reiss K, Khalili K, Del Valle L (2007) Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy. Am J Pathol 170:1291–1304
76. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802–812
77. Radhakrishnan S, Otte J, Enam S, Del Valle L, Khalili K, Gordon J (2003) JC virus-induced changes in cellular gene expression in primary human astrocytes. J Virol 77:10638–10644
78. Ray M, Curtis JR, Baddley JW (2014) A case report of progressive multifocal leukoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis 73:1429–1430
79. Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, Tyler KL (2002) Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol 59:1930–1936
80. Richardson EP Jr, Webster HD (1983) Progressive multifocal leukoencephalopathy: its pathological features. Prog Clin Biol Res 105:191–203
81. Rodriguez M, Prayoonwiwat N, Howe C, Sanborn K (1994) Proteolipid protein gene expression in demyelination and remyelination of the central nervous system: a model for multiple sclerosis. J Neuropathol Exp Neurol 53:136–143
82. Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372:1476–1478
83. Rushing EJ, Liappis A, Smirniotopoulos JD, Smith AB, Henry JM, Man Y-G, Nelson AM (2008) Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol Exp Neurol 67:819–827
84. Schippling S, Kempf C, Buchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R (2013) JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment. Ann Neurol 74:622–626
85. Schmedt N, Andersohn F, Garbe E (2012) Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 21:1216–1220
86. Schmidbauer M, Budka H, Shah KV (1990) Progressive multifocal leukoencephalopathy (PML) in AIDS and in the pre-AIDS era. A neuropathological comparison using immunocytochemistry and in situ DNA hybridization for virus detection. Acta Neuropathol 80:375–380
87. Schwab N, Hohn KG, Schneider-Hohendorf T, Metz I, Stenner M-P, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Bruck W, Wiendl H (2012) Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 18:335–344
88. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Gobel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kumpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 81:865–871
89. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84:1499–1504
90. Stork L, Bruck W, Bar-Or A, Metz I (2015) High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol 129:467–468
91. Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, Lima Bomfim I, Fogdell-Hahn A, Link J, Alfredsson L, Sondergaard HB, Hillert J, Oturai AB, Hemme B, Kockum I, Olsson T (2014) JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog 10:e1004084
92. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L (2009) Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 5:e1000368
93. Taguchi F, Kajioka J, Miyamura T (1982) Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 26:1057–1064
94. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, Koralnik IJ (2009) Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199:881–888
95. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437
96. Tavazzi E, White MK, Khalili K (2012) Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol 22:18–32
97. Tur C, Montalban X (2014) Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs 28:641–648
98. Tyler KL (2009) Emerging viral infections of the central nervous system: part 2. Arch Neurol 66:1065–1074
99. Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO, Tritsmans L, Stuyver LJ (2015) JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol 89:1340–1347
100. Vanneste JA, Bellot SM, Stam FC (1984) Progressive multifocal leukoencephalopathy presenting as a single mass lesion. Eur Neurol 23:113–118
101. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F (2005) Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 109:449–455
102. von Einsiedel RW, Samorei IW, Pawlita M, Zwissler B, Deubel M, Vinters HV (2004) New JC virus infection patterns by in situ polymerase chain reaction in brains of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neurovirol 10:1–11
103. Waggoner J, Martinu T, Palmer SM (2009) Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 28:395–398
104. Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O (2013) An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Multiple Scler 19:1137–1144
105. Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kumpfel T, Maurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung H-P, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O (2014) Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:792–801
106. Wattjes MP, Barkhof F (2014) Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27:260–270
107. Weber F, Goldmann C, Kramer M, Kaup FJ, Pickhardt M, Young P, Petry H, Weber T, Luke W (2001) Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 49:636–642
108. Wisniewski HM, Bloom BR (1975) Primary demyelination as a nonspecific consequence of a cell-mediated immune reaction. J Exp Med 141:346–359
109. Wuthrich C, Cheng YM, Joseph JT, Kesari S, Beckwith C, Stopa E, Bell JE, Koralnik IJ (2009) Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 68:15–25
110. Wuthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, Ropper AH, Viscidi RP, Koralnik IJ (2009) Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 65:742–748
111. (+) T cells with JCV-infected glial cells. J Neurovirol 12:116–128
112. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M (2012) Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72:779–787
113. + hematopoietic progenitor cells in humans. Blood 111:3893–3895